Levetiracetam Ucb

Levetiracetam, the active ingredient in Levetiracetam Ucb, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that reduces abnormal neuronal firing in the brain. - Partial‑onset seizures: helps achieve seizure control in focal epilepsy. - Generalized tonic‑clonic seizures: reduces the frequency and severity of convulsive episodes. - Myoclonic seizures: diminishes sudden muscle jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: occasional stomach upset. - Nasal congestion: mild upper‑respiratory discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or breathing difficulty. - Mood disorders: depression or suicidal thoughts. - Hematologic abnormalities: low blood cell counts. - Hepatic dysfunction: elevated liver enzymes. - Severe skin reactions: Stevens‑Johnson syndrome. - Multiorgan failure: extremely rare but life‑threatening.

Before initiating therapy, consider the following safety measures. - Renal function: adjust dose in patients with impaired clearance. - Psychiatric history: monitor for mood changes or suicidal ideation. - Concomitant CNS depressants: assess additive sedation risk. - Pregnancy: discuss potential risks with a healthcare professional. - Lactation: evaluate infant exposure through breast milk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam concentrations. - Phenytoin: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Alcohol: increased sedation and dizziness. - Opioids: heightened central nervous system depression. - Fluoroquinolones: potential for enhanced neurotoxicity. - Other antiepileptics: assess cumulative side‑effect burden.